MitoSense, Inc.

08/31/2026

Wonderful story about Norway’s King Harald V and MitoSense founder, Dr. Robert Elliott.

King Harald V of Norway was a good man, down to Earth and had a sense of humor.

I’ll never forget a number of years ago, both myself and the late American medical pioneer, Dr. Bob Elliott, were invited to have an after dinner drink with the King and discuss Dr. Elliott’s research.

Dr. Elliott began by saying, "Your majesty, as a little boy growing up in the Mississippi Delta, I could have never imagined I’d be meeting and having dinner with a King. As they say where I come from, I’m in high cotton tonight!"
King Harald, who actually went to grammar school in the U.S. after fleeing the N***s at an early age, responded, "Dr. Elliott, I know what high cotton is!" Everyone who heard it cracked up and the conversation was just getting started.

RIP King Harald V 🇳🇴

08/03/2026

Meet the MitoSense team at , Booth #1106.

We look forward to discussing mitochondrial transplantation, traumatic brain injury research, military medicine, and our collaborations across the federal and scientific communities.

07/25/2026

Big news in mitochondrial medicine.

MitoSense and Aquila Health are partnering to build AI-ready, governed data infrastructure using Aquila’s TREUE standard.

The goal: connect fragmented patient data so researchers can better understand disease progression and treatment response in ALS, Parkinson’s, Alzheimer’s, and more.

https://www.mitosenseinc.com/post/mitosense-aquila-partnership-ai-data-infrastructure

07/15/2026

The University of Pittsburgh is leading the way in academia for space medicine.

We are honored to enter into a MOU with Pitt to advance mitochondrial transplantation and novel therapies targeting mitochondria dysfunction associated with space travel, aging, Long COVID and more.

Collaboration will evaluate mitochondrial and microRNA biomarkers, multi-omics analysis, and research tools relevant to astronaut health, deep-space travel, and post-viral disease.

07/04/2026

07/02/2026

ALS. TBI. Two of the most difficult neurological challenges in medicine.

That’s exactly where MitoSense believes bold science belongs.

We’re proud to be advancing work with the U.S. Department of Veterans Affairs toward an ALS clinical program while collaborating with researchers at Walter Reed to explore Mitochondria Organelle Transplantation (MOT™) for traumatic brain injury.

By bringing together leading scientists, clinicians, and institutions, we’re working to accelerate the development of new therapeutic approaches for patients who urgently need better options.

We’re just getting started.

06/02/2026

This Lou Gehrig Day, MitoSense honors the legacy and courage of the baseball great.

And we are honored to be officially working with the U.S. Department of Veterans Affairs to develop a treatment for .

This is a fight we must win.

lou Gherig speaks on July 4th about his ALS disease

05/26/2026

reminds us why innovation matters. Every breakthrough starts with a belief that better treatments are possible.

MitoSense is proud to support the fight for progress, hope, and meaningful impact through mitochondrial science.

04/23/2026

"And it may just be the biggest medical breakthrough you've never heard of until now."

— Dr. Robert Lufkin, M.D. on
Organelle Transplantation

Why are more physicians paying attention to mitochondrial medicine?

Watch the full conversation:

What if aging, ALS, Parkinson's, stroke, and diabetes all share a single upstream cause — and the fix is a transplant the size of a bacterium? Dr. Catherine ...